MedCity News

Integris Health to Join Risant Health as Health System Dealmaking Stays Active

CMS Is Regulating the Wrong Thing — Here’s How to Fix Remote Patient Monitoring Without Losing the Care

Why should Medicare determine who is qualified to provide remote monitoring by asking who employs the nurse, rather than who is accountable for the patient's care?

By Anish Sebastian

MedCity Influencers

Mental Health Care Was Never Built for Everyone — AI Won’t Fix That

Companies aren't slowing down to ask if AI is ready for mental health; they're racing to build it in. Encoding the same unexamined standards into these tools means repeating the systemic issues marginalized groups have lived with for far too long.

By Josephine Mora

How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes

BTK inhibitor has become an important treatment option for certain B-cell malignancies.

By Samuel Turner

Latest Video

Latest News

Health Tech

Midstream Health Snags $20M to Provide Health Systems More Financial Stability

Midstream's Series A round was led by Valtruis, and included participation from Andreessen Horowitz (a16z), Foundry and CommonSpirit Ventures.

By Marissa Plescia

BioPharma, Startups

Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic

Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals.

By Frank Vinluan

Devices & Diagnostics

MMI Raises $125M to Expand Robotic Microsurgery and Explore New Treatments

Medical Microinstruments (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical System and investigate new applications for microsurgery, including an experimental approach to treat Alzheimer’s disease.

By Jenna Congdon

MedCity Influencers

What the Midterms Mean for Healthcare and the Investors Betting on It

One question on everyone’s mind is what the impact of the midterm elections will be on the US healthcare system in the near and long term - here are 3 possible outcomes

By Jason Robart

MedCity Influencers

Prestige Is a Business Model

An employer that treats board disclosure, community benefit reporting, and contracting terms as three separate conversations is missing that they are the same conversation.

By Dana Y. Lujan

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

Consumer / Employer, Policy

close-up studio macro shot of various pills on US dollar bills.

Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMs

The Department of Labor finalized a rule that seeks to bring more transparency into PBM compensation.

By Marissa Plescia

BioPharma, Pharma

Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’

Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy.

By Frank Vinluan

MedCity Influencers

It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements

For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance.

By Paul R. Piccigallo

MedCity Influencers

A Meaningful Signal on Palliative Care – But Not Yet a Benefit

CMS asked the right questions - the ones that will determine whether any future benefit actually reaches these patients.

By Jill Schwartz-Chevlin

Consumer / Employer, Health Tech

What’s Driving the Rise of Consumer Diagnostics?

At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics.

By Marissa Plescia

BioPharma, Pharma

BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year.

By Frank Vinluan

MedCity Influencers

Beyond a Score: Putting The Patient Experience at the Heart of OCD Innovation

Scientific progress only really matters if it changes what life looks like for those living with OCD. That’s because for someone who has spent years losing hours to their obsessions and compulsions, meaningful progress should mean a significant change in their lives.

By Hannah Ellis and Nick Sireau

3 Ways ProgenyHealth Can Transform Maternity and Infant Health, Claims Management

Pregnancy and NICU admissions are among the most complex areas in healthcare. A new report from ProgenyHealth highlights how the company can work with Medicaid and commercial health plans to uncover insights and hidden risks critical to improving maternal and infant care and reducing costs.

By Stephanie Baum

Payers, Policy

Senators Investigate Insurers’ Role in Removing Thousands from ACA Coverage

Democratic senators are investigating 10 insurers’ role in the Trump administration’s termination of 760,000 ACA enrollees’ coverage over suspected fraud.

By Marissa Plescia

BioPharma, Pharma

Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic.

By Frank Vinluan